Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Express Scripts
Moodys
McKinsey
Dow

Last Updated: August 11, 2022

Investigational Drug Information for L-Lysine


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug L-Lysine?

L-Lysine is an investigational drug.

There have been 21 clinical trials for L-Lysine. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2002.

The most common disease conditions in clinical trials are Carcinoma, Breast Neoplasms, and Syndrome. The leading clinical trial sponsors are National Cancer Institute (NCI), Roswell Park Cancer Institute, and Jonsson Comprehensive Cancer Center.

Recent Clinical Trials for L-Lysine
TitleSponsorPhase
Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantJonsson Comprehensive Cancer CenterPhase 1
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast CancerFred Hutchinson Cancer Research CenterPhase 1
Reparixin as add-on Therapy to Standard of Care to Limit Disease Progression in Adult Patients With COVID-19.Dompé Farmaceutici S.p.APhase 3

See all L-Lysine clinical trials

Clinical Trial Summary for L-Lysine

Top disease conditions for L-Lysine
Top clinical trial sponsors for L-Lysine

See all L-Lysine clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Express Scripts
Moodys
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.